Log In
Print this Print this

Biosimilar bevacizumab (BOW030)

  Manage Alerts
Collapse Summary General Information
Company Epirus Biopharmaceuticals Inc.
DescriptionBiosimilar of bevacizumab, a humanized mAb against VEGF
Molecular Target Vascular endothelial growth factor (VEGF)
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today